NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $18.59 -2.45 (-11.64%) As of 06/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendFinancialsInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Aerovate Therapeutics Stock (NASDAQ:AVTE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aerovate Therapeutics alerts:Sign Up Key Stats Today's Range$17.35▼$20.7450-Day Range$13.26▼$26.8552-Week Range$89.95▼$99.05Volume2.69 million shsAverage Volume53,591 shsMarket Capitalization$538.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. By leveraging a proprietary aerosol delivery platform, the company aims to deliver potent small-molecule anti-fibrotic and anti-inflammatory agents directly to the lungs, thereby maximizing local drug exposure while minimizing systemic side effects. The company’s lead product candidate is an inhaled formulation of an established anti-fibrotic agent currently in early-phase clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). In addition to its IPF program, Aerovate is advancing preclinical molecules designed to target other chronic lung conditions, including scleroderma-related interstitial lung disease and chronic obstructive pulmonary disease. Each program is engineered to exploit the company’s aerosol technology, which is designed to enhance pulmonary deposition and improve patient tolerability compared with oral therapies. Founded in 2020 and headquartered in the United States, Aerovate Therapeutics has assembled a team of experienced drug developers and clinicians to shepherd its pipeline through clinical development. The company collaborates with leading research institutions and regulatory authorities to support trial design and anticipate broader geographic expansion, positioning Aerovate to address significant unmet needs in fibrotic and inflammatory lung diseases worldwide.AI Generated. May Contain Errors. Read More Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTE Stock News HeadlinesAerovate Therapeutics (NASDAQ:AVTE) Shares Down 5.3% - Here's What HappenedMay 27, 2026 | americanbankingnews.comJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 MillionApril 28, 2025 | globenewswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. | Brownstone Research (Ad)Aerovate Stockholders Approve Merger Proposal With Jade BiosciencesApril 23, 2025 | nasdaq.comAerovate Therapeutics stockholders approve proposed merger with Jade BiosciencesApril 23, 2025 | markets.businessinsider.comAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related ProposalsApril 21, 2025 | prnewswire.comAerovate Therapeutics declares special cash dividend, estimated $2.40 per shareApril 10, 2025 | markets.businessinsider.comAerovate Therapeutics sees $67.6M-$69.6M dividend in connection with JadeApril 9, 2025 | markets.businessinsider.comSee More Headlines AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $15.43 at the start of the year. Since then, AVTE stock has increased by 20.5% and is now trading at $18.59. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings data on Friday, April, 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.50) by $7.35. When did Aerovate Therapeutics' stock split? Shares of Aerovate Therapeutics reverse split before market open on Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $122 million in an initial public offering (IPO) on Tuesday, June 29th 2021. The company issued 8,682,142 shares at $13.00-$15.00 per share. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aerovate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings4/25/2025Today6/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTE CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year Founded2018Profitability EPS (Trailing Twelve Months)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-90.19% Return on Assets-77.47% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book4.69Miscellaneous Outstanding Shares28,985,000Free Float21,685,000Market Cap$538.83 million OptionableOptionable Beta0.95 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AVTE) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
